1. Roche Canada. COLUMVI® (glofitamab for injection) receives Health Canada authorization with conditions for adult patients with relapsed or refractory diffuse large B-cell lymphoma [media release]. 25 Mar 2023. https://www.rochecanada.com/en/media/roche-canada-news/COLUMVI-Glofitamab-for-Injection-Receives-Health-Canada-Authorization.html.
2. Roche Canada. COLUMVI® product monograph. 2023. https://www.rochecanada.com/content/dam/rochexx/roche-ca/products/ConsumerInformation/MonographsandPublicAdvisories/columvi/Columvi_PM_E.pdf. Accessed 01 May 2023.
3. European Medicines Agency. Columvi. 2023. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/columvi. Accessed 01 May 2023.
4. Roche. FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma [media release]. 06 Jan 2023. http://www.roche.com.
5. Chugai Pharmaceutical Co. Conference on FY2022.12 2Q financial results. 21 Jul 2022. https://www.chugai-pharm.co.jp/cont_file_dl.php?f=FILE_5_60.pdf&src=%5b%250%5d,%5b%251%5d&rep=137,60. Accessed 01 May 2023.